Titan‑1 Technology: A New Era of Microbiome Precision
AI-Powered Microbiome Discovery for the Future of Health
Titan‑1™ is Intus Biosciences’ advanced microbiome technology platform, built to be high resolution, high throughput, and database independent. By sequencing beyond 16S and combining results with proprietary AI analysis, it delivers highly accurate, actionable insights that surpass the limits of traditional microbiome testing.
With full control over every step—from sample lysis to deep AI-driven interpretation—Titan‑1™ functions as a true ‘sample to solution’ platform. This integrated approach enables precise strain-level detection, reveals novel microbes, and sets a new standard for microbiome research, diagnostics, and therapeutic development.
With full control over every step—from sample lysis to deep AI-driven interpretation—Titan‑1™ functions as a true ‘sample to solution’ platform. This integrated approach enables precise strain-level detection, reveals novel microbes, and sets a new standard for microbiome research, diagnostics, and therapeutic development.
Titan-1™
The Technology Behind Titan-1™
01
High-Resolution Amplicon Sequencing
02
AI-Driven Bioinformatics
03
High Sensitivity with Fast Turnaround
04
Clinical Standards
The difference
Strain-Level Precision Through Innovation
What sets Titan‑1™ apart is its unparalleled resolution and scalability. While traditional methods might detect broad microbial categories, Titan‑1™ provides actionable, strain-level data that can reveal key health indicators, such as distinguishing a harmful strain of E. coli from a commensal one. Its ability to identify and monitor novel microbial strains has broad implications across gut health, immunity, longevity, and even cancer and disease diagnostics.
Additionally, the AI-enhanced analytics pipeline allows Titan‑1™ to track microbiome shifts over time, offering clinicians, researchers, and consumers the ability to understand not just what microbes are present, but how they’re evolving and interacting in the context of disease or therapy.
Additionally, the AI-enhanced analytics pipeline allows Titan‑1™ to track microbiome shifts over time, offering clinicians, researchers, and consumers the ability to understand not just what microbes are present, but how they’re evolving and interacting in the context of disease or therapy.
